Trials / Recruiting
RecruitingNCT03961776
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 39 (estimated)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
Detailed description
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI-guided radiotherapy by on-board DWI sequences | The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes. |
Timeline
- Start date
- 2020-06-08
- Primary completion
- 2022-05-01
- Completion
- 2027-05-01
- First posted
- 2019-05-23
- Last updated
- 2021-05-06
Locations
2 sites across 2 countries: United States, France
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03961776. Inclusion in this directory is not an endorsement.